
USD
$0.00
(0.00%
)At Close (As of Dec 15, 2025)
$73.84M
Market Cap
-
P/E Ratio
-13.54
EPS
$46.80
52 Week High
$3.76
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Total Assets | $70M |
| Total Current Assets | $62M |
| Cash And Cash Equivalents At Carrying Value | $37M |
| Cash And Short Term Investments | $37M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $8M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $20M |
| Other Current Assets | $5.2M |
| Other Non Current Assets | - |
| Total Liabilities | $99M |
| Total Current Liabilities | $22M |
| Current Accounts Payable | $2.6M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $3.5M |
| Total Non Current Liabilities | $79M |
| Capital Lease Obligations | $8.4M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $8.4M |
| Other Current Liabilities | $16M |
| Other Non Current Liabilities | $46K |
| Total Shareholder Equity | -$29M |
| Treasury Stock | - |
| Retained Earnings | -$618M |
| Common Stock | $8K |
| Common Stock Shares Outstanding | $6.3M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Aligos Therapeutics, Inc. (ALGS) is an innovative clinical-stage biopharmaceutical company headquartered in South San Francisco, California, specializing in the development of groundbreaking therapies for viral infections and liver diseases. With a robust pipeline targeting chronic hepatitis B and liver fibrosis, Aligos is dedicated to addressing significant unmet medical needs through cutting-edge scientific research and strategic partnerships. The company's commitment to advancing transformative healthcare solutions, combined with its strong focus on high-impact therapeutic areas, makes it an attractive investment prospect for institutional investors seeking growth opportunities in the biopharmaceutical landscape.